Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Analyst Ratings Changes

Several brokerages have recently weighed in on VRCA. Royal Bank of Canada cut shares of Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating and lowered their price objective for the stock from $16.00 to $4.00 in a research note on Wednesday, May 25th. Needham & Company LLC cut shares of Verrica Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, May 25th. Finally, HC Wainwright decreased their target price on shares of Verrica Pharmaceuticals to $11.00 in a research note on Monday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $14.60.

Verrica Pharmaceuticals Trading Up 1.4 %

NASDAQ:VRCA opened at $3.74 on Friday. Verrica Pharmaceuticals has a 12 month low of $1.77 and a 12 month high of $14.79. The stock has a market cap of $102.92 million, a price-to-earnings ratio of -2.49 and a beta of 2.16. The company's 50 day moving average is $2.92 and its two-hundred day moving average is $5.53.

Insider Buying and Selling at Verrica Pharmaceuticals

In related news, insider Christopher G. Hayes acquired 7,500 shares of the business's stock in a transaction on Monday, July 11th. The stock was acquired at an average cost of $3.40 per share, with a total value of $25,500.00. Following the acquisition, the insider now directly owns 15,714 shares in the company, valued at approximately $53,427.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Ted White acquired 23,809 shares of the business's stock in a transaction on Tuesday, July 5th. The stock was acquired at an average cost of $2.10 per share, with a total value of $49,998.90. Following the acquisition, the chief executive officer now directly owns 29,466 shares in the company, valued at approximately $61,878.60. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christopher G. Hayes acquired 7,500 shares of the business's stock in a transaction on Monday, July 11th. The shares were bought at an average cost of $3.40 per share, with a total value of $25,500.00. Following the completion of the acquisition, the insider now owns 15,714 shares in the company, valued at $53,427.60. The disclosure for this purchase can be found here. Insiders purchased a total of 1,703,689 shares of company stock valued at $3,587,497 in the last three months. 43.50% of the stock is currently owned by corporate insiders.